Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism

Lee,Young  Ju; Kim,Ji  Eun; Hwang,In  Sik; Kwak,Moon  Hwa; Lee,Jae  Ho; Jung,Young  Jin; An,Beum  Soo; Kwon,Hyeog  Soong; Kim,Byoung  Chul; Kim,Seon  Jong; Kim,Joo  Man; Hwang,Dae  Youn

doi:10.3892/mmr.2013.1404

Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism

Authors:
- Young Ju Lee
- Ji Eun Kim
- In Sik Hwang
- Moon Hwa Kwak
- Jae Ho Lee
- Young Jin Jung
- Beum Soo An
- Hyeog Soong Kwon
- Byoung Chul Kim
- Seon Jong Kim
- Joo Man Kim
- Dae Youn Hwang
View Affiliations

Affiliations: Department of Biomaterials Science, College of Natural Resources and Life Sciences, Pusan National University, Miryang, Gyeongsangnam‑do 627‑706, Republic of Korea, Department of Applied IT and Engineering, College of Natural Resources and Life Sciences, Pusan National University, Miryang, Gyeongsangnam‑do 627‑706, Republic of Korea
Published online on: March 28, 2013 https://doi.org/10.3892/mmr.2013.1404
Pages: 1571-1578

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD) is closely associated with significant defects in glucose metabolism. To investigate whether AD pathology induced by overexpression of human mutant presenilin 2 (PS2) protein induces changes in glucose metabolism, glucose‑related factors were analyzed in the brain of 12‑month‑old neuron‑specific enolase (NSE)/hPS2m transgenic (Tg) mice. NSE/hPS2m Tg mice used in this study showed AD‑like phenotypes such as the accumulation of Aβ‑42, the increase of γ‑secretase activity and Tau hyperphosphorylation. A significant increase of glucose levels accompanied by a decrease of insulin levels was detected in NSE/hPS2m Tg mice, while the expression levels of insulin receptors were significantly decreased in NSE/hPS2m Tg mice compared to the non‑Tg littermates without affecting the insulin‑like growth factor (IGF) receptor. Moreover, the levels of AKT phosphorylation involved in the downregulation of the insulin receptor signaling pathway were reduced in the brain of NSE/hPS2m Tg mice compared with non‑Tg littermate, although the levels of glycogen synthase kinase 3 (GSK‑3) β phosphorylation were higher in the NSE/hPS2m Tg mice compared to non-Tg littermates. Furthermore, the levels of the expression of Glut‑1 and ‑3 were significantly reduced in the NSE/hPS2m Tg mice compared to those of control mice without affecting the Glut‑4 protein expression between the two groups of mice. In particular, the levels of the Aβ‑42 peptide in the brain of insulin‑treated NSE/hPS2m Tg mice were found to be slightly lower compared with those of the Aβ‑42 peptide in the non‑treated PS2 transgenic mice. Thus, the data presented in this study provide strong evidence that key factors of glucose metabolism are closely associated with the AD pathology induced by the hPS2m protein, and that insulin can serve as a potential therapeutic for AD patients.

View Figures

View References

1	Gsell W, Moll G, Sofic E and Riederer P: Cholinergic and monoaminergic neurotransmitter systems in patients with Alzheimer’s disease and senile dementia of Alzheimer type: a clinical evaluation. Dementias-neurochemistry, neuropathology, neuroimaging, neuropsychology and genetics. Maurer K: Braunschweig; Vieweg: pp. 25–51. 1993
2	Hoyer S: Senile dementia and Alzheimer’s disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 10:447–478. 1986.
3	Hoyer S, Oesterreich K and Wanger O: Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol. 235:143–148. 1988. View Article : Google Scholar : PubMed/NCBI
4	Hoyer S, Nitsch R and Oesterreich K: Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect. 3:1–14. 1991. View Article : Google Scholar
5	Bigl M, Apelt J, Eschrich K and Schliebs R: Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J Neural Transm. 110:77–94. 2003.PubMed/NCBI
6	Mooradian AD, Chung HC and Shah GN: Glut-1 expression in the cerebral of patients with Alzheimer’s disease. Neurobiol Aging. 18:469–474. 1997.
7	Simpson IA, Chundu KR, Davies-Hill T, Honer WG and Davies P: Decreased concentrations of Glut1 and Glut3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol. 35:546–551. 1994.PubMed/NCBI
8	Baskin DG, Wilcox BJ, Figlewicz DP and Dorsa DM: Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 11:107–111. 1988. View Article : Google Scholar : PubMed/NCBI
9	Wozniak M, Rydzewski B, Baker SP and Raizada MK: The cellular and physiological actions of insulin in the central nervous system. Neurochem Int. 22:1–10. 1993. View Article : Google Scholar : PubMed/NCBI
10	Harvankova J, Schmerchel D, Roth J and Brownstein M: Identification of insulin in rat brain. Proc Natl Acad Sci USA. 75:5737–5741. 1978. View Article : Google Scholar : PubMed/NCBI
11	Devasker SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK and Zahm DS: Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem. 269:8445–8454. 1994.PubMed/NCBI
12	Hoyer S, Prem L, Sorbi S and Amsucci L: Stimulation of glycolytic key enzymes in cerebral cortex by insulin. Neuroreport. 4:991–993. 1993. View Article : Google Scholar : PubMed/NCBI
13	de Pablo F and de la Rosa E: The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci. 18:143–150. 1995.PubMed/NCBI
14	Calissano P, Ciotti MT, Battistini L, Zona C, Angelini A, Merlo D and Mercanti D: Recombination insulin-like growth factor I exerts a trophic action and confers glutamate sensitivity on glutamate-resistant cerebellar cells. Proc Natl Acad Sci USA. 90:8752–8756. 1993. View Article : Google Scholar : PubMed/NCBI
15	Quirion R, Araujo DM, Lapehak PA, Seto D and Chabot JG: Growth factors and lymphokines: modulators of cholinergic neuronal activity. Can J Neurol Sci. 18:390–393. 1991.PubMed/NCBI
16	Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ and White MF: Structure of the insulin receptor substrate ISR-1 defines a unique signal transduction protein. Nature. 352:73–77. 1991. View Article : Google Scholar : PubMed/NCBI
17	White MF and Kahn CR: The insulin signaling system. J Biol Chem. 269:1–4. 1994.
18	Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissle KW, Jellinger K and Riederer P: Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm. 105:423–438. 1998.
19	Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS and Kim YK: Alterations in behavior, amyloid β-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer’s disease. FASEB J. 16:805–813. 2002.
20	Hwang DY, Cho JS, Oh JH, Shim SB, Jee SW, Lee SH, Seo SJ, Lee SK, Lee SH and Kim YK: Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer’s disease. Neurochem Res. 30:1009–1019. 2005.PubMed/NCBI
21	Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, McNeish JD and Coleman KG: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 112:197–208. 2003. View Article : Google Scholar : PubMed/NCBI
22	Meijer L, Flajolet M and Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 25:471–480. 2004. View Article : Google Scholar : PubMed/NCBI
23	Boyt AA, Taddei TK, Hallmayer J, Helmerhorst E, Gandy SE, Craft S and Martins RN: The effect of insulin and glucose on the plasma concentration of Alzheimer’s amyloid precursor protein. Neuroscience. 95:727–734. 2000.
24	Meier-Ruge WA and Bertoni-Freddari C: Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann N Y Acad Sci. 826:229–241. 1997. View Article : Google Scholar : PubMed/NCBI
25	Hoyer S: Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol. 35:1363–1372. 2000. View Article : Google Scholar : PubMed/NCBI
26	Hoyer S: The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm. 109:341–360. 2002. View Article : Google Scholar : PubMed/NCBI
27	Oyama F, Sawamura N, Kobayashi K, Morishima-Kawashima M, Kuramochi T, Ito M, Tomita T, Maruyama K, Saido TC, Iwatsubo T, Capell A, Walter J, Grunberg J, Ueyama Y, Haass C and Ihara Y: Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem. 71:313–322. 1998. View Article : Google Scholar : PubMed/NCBI
28	Polonsky KS and Rubenstein AH: C-peptide as a measure of the secretion an hepatic extraction of insulin. Pitfalls and limitations Diabetes. 33:486–494. 1984. View Article : Google Scholar : PubMed/NCBI
29	Kurochkin IV and Goto S: Alzheimer’s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345:33–37. 1994.
30	Authier F, Posner BI and Bergeron JJ: Insulin-degrading enzyme. Clin Invest Med. 19:149–160. 1996.
31	Perez A, Morelli L, Cresto JC and Castano EM: Degradation of soluble amyloid beta-peptides 1–40, 1–42, and the Dutch variant 1–40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res. 25:247–255. 2000.
32	Vekrellis K, Ye Z, Qui WQ, Walsh D, Hartley D, Cheseneau V, Rosner MR and Selkoe DJ: Neurons regulate extracellular levels of amyloid-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 20:1657–1665. 2000.PubMed/NCBI
33	Henneberg N and Hoyer S: Short-term or long-term intracerebroventricular (i. cv) infusion of insulin exhibits a discrete anabolic effect on cerebral energy metabolism in the rat. Neurosci Lett. 175:153–156. 1994. View Article : Google Scholar : PubMed/NCBI
34	De Keyser J, Wilczak N and Goosens A: Insulin-like growth factor-1 receptor densities in human frontal cortex and white matter during aging, in Alzheimer’s disease, and in Huntington’s disease. Neurosci Lett. 172:93–96. 1994.PubMed/NCBI
35	Crew FT, McElhaney R, Freund G, Ballinger WE Jr and Raizada MK: Insulin-like growth factor I receptor binding in brains of Alzheimer’s and alcoholic patients. J Neurochem. 58:1205–1210. 1992.
36	Stein TD and Johnson JA: Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased level of transthyretin and the activation of cell survival pathways. J Neurosci. 22:7380–7388. 2002.PubMed/NCBI
37	Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins R, Fleschman S, Rice V, Newcomber JW and Cryer PE: Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci. 107:926–940. 1993. View Article : Google Scholar : PubMed/NCBI
38	Manning CA, Ragozzino ME and Gold PE: Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer’s type. Neurobiol Aging. 14:523–528. 1993.
39	Harr SD, Simonian NA and Hyman BT: Functional alterations in Alzheimer’s disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol. 54:38–41. 1995.
40	Sivitz WS, DeSautel PS and Pessin JE: Regulation of the glucose transporter in developing rat brain. Endocrinology. 124:1875–1880. 1989. View Article : Google Scholar : PubMed/NCBI
41	Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD and Krohn AJ: Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 28:809–822. 2003.